Romano Alessandra, Conticello Concetta, Cavalli Maide, Vetro Calogero, La Fauci Alessia, Parrinello Nunziatina Laura, Di Raimondo Francesco
Department of Clinical and Molecular Biomedicine, Haematology Section, University of Catania, Catania, Italy ; Fondazione Veronesi, Roma, Italy ; Division of Hematology, AOU "Policlinico-Vittorio Emanuele", Catania, Italy.
Division of Hematology, AOU "Policlinico-Vittorio Emanuele", Catania, Italy.
Biomed Res Int. 2014;2014:198539. doi: 10.1155/2014/198539. Epub 2014 Jun 11.
Multiple Myeloma (MM) is a systemic hematologic disease due to uncontrolled proliferation of monoclonal plasma cells (PC) in bone marrow (BM). Emerging in other solid and liquid cancers, the host immune system and the microenvironment have a pivotal role for PC growth, proliferation, survival, migration, and resistance to drugs and are responsible for some clinical manifestations of MM. In MM, microenvironment is represented by the cellular component of a normal bone marrow together with extracellular matrix proteins, adhesion molecules, cytokines, and growth factors produced by both stromal cells and PC themselves. All these components are able to protect PC from cytotoxic effect of chemo- and radiotherapy. This review is focused on the role of immunome to sustain MM progression, the emerging role of myeloid derived suppressor cells, and their potential clinical implications as novel therapeutic target.
多发性骨髓瘤（MM）是一种系统性血液疾病，由骨髓（BM）中单核浆细胞（PC）的失控增殖引起。在其他实体癌和液体癌中，宿主免疫系统和微环境对浆细胞的生长、增殖、存活、迁移以及对药物的抗性起着关键作用，并导致了MM的一些临床表现。在MM中，微环境由正常骨髓的细胞成分以及基质细胞和浆细胞自身产生的细胞外基质蛋白、粘附分子、细胞因子和生长因子组成。所有这些成分都能够保护浆细胞免受化疗和放疗的细胞毒性作用。本综述聚焦于免疫组在维持MM进展中的作用、髓系来源抑制细胞的新作用及其作为新型治疗靶点的潜在临床意义。
